CF
DNTH icon

Corebridge Financial’s Dianthus Therapeutics DNTH Stock Holding History

Corebridge Financial’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,709
Closed -$212K – 789
2025
Q1 		$212K Sell
11,709
-174
-1% -$3.83K ﹤0.01% 2043
2024
Q4 		$259K Sell
11,883
-897
-7% -$23.1K ﹤0.01% 2020
2024
Q3 		$350K Sell
12,780
-79
-0.6% -$2.2K ﹤0.01% 1916
2024
Q2 		$333K Buy
+12,859
New +$309K ﹤0.01% 1910

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corebridge Financial's DNTH Position: Q2 2025 in Review

Corebridge Financial sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 11,709 shares — an estimated $212K sold.

Corebridge Financial first reported a position in DNTH in Q2 2024 and held it in 4 quarters. The position peaked at $350K in Q3 2024. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

  • Corebridge Financial reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 11,709 Dianthus Therapeutics shares in Q2 2025, an estimated $212K.
  • Corebridge Financial first reported a position in Dianthus Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Dianthus Therapeutics position peaked at $350K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.